利奈唑胺联合环丝氨酸治疗耐多药肺结核患者的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Linezolid combined with Cycloserine in the treatment of patients with multi-drug resistant pulmonary tuberculosis(MDR-PTB).Methods Eighty-four MDR-PTB patients who were hospitalized or outpatient in Jingzhou Chest Hospital from March 2017 to December 2019 were selected as the research subjects.According to random number table method,the patients were divided into two groups,with 42 cases in each group.Patients in both groups received basic treatment.Patients in the control group were additionally treated with Cycloserine,and patients in the observation group were additionally treated with Linezolid.The total effective rate,improvement time of clinical symptoms and the occurrence of adverse drug reactions were compared between the two groups.Results The total effective rate of observation group(88.10%)was higher than that of control group(66.67%),and the difference was statistically significant(P<0.05).The reduction time of focus volume,the time of sputum culture turning negative,the time of acid-fast staining smear turning negative and the time of cavity closing in the observation group were all shorter than those in the control group,with statistically significant differences(P<0.05).There was no statistical significance in the total incidence of adverse drug reactions between the two groups during treatment(P>0.05).Conclusion The treatment of Linezolid combined with Cycloserine for MDR-PTB patients has a significant effect.It can improve clinical symptoms,and it will not increase the incidence of adverse drug reactions.

Key words： Linezolid Cycloserine Multi-drug resistant pulmonary tuberculosis Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG An-jin
	FAN Tian-qiong
	YANG Cheng-ming
	CHENG Shi-si
	WANG Jie

Cite this article:

ZENG An-jin,FAN Tian-qiong,YANG Cheng-ming, et al. Clinical effect of Linezolid combined with Cycloserine in the treatment of patients with multi-drug resistant pulmonary tuberculosis[J]. 中国当代医药, 2021, 28(22): 194-196转200.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I22/194

[1]	王飞，陈彬，周琳，等.耐多药肺结核患者抗结核药物所致不良反应发生情况[J].中华传染病杂志，2017，35（2）：83-87.
[2]	陈胜兰，祝春亚，周华，等.利奈唑胺治疗耐甲氧西林金黄色葡萄球菌血流感染的效果及安全性[J].中华医学杂志，2017，97（14）：1084-1088.
[5]	邓飞，王勇.利奈唑胺对耐药肺结核患者血清降钙素原、红细胞沉降率及C 反应蛋白的影响[J].四川医学，2018，39（7）：801-804.
[6]	闫丽萍，吴哲渊，张祖荣，等.初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究[J].中国防痨杂志，2017，39（1）：33-38.
[3]	Liao S，Cai C，Huo FM，et al.Trends in drug-resistant tuberculosis in China：Data from a clinical tuberculosis centre[J].Int J Tuberc Lung Dis，2017，21（9）：990-995.
[4]	Lange C，Chesov D，Heyckendorf J，et al.Drug-resistant tuberculosis：An update on disease burden，diagnosis and treatment[J].Respirology，2018，23（7）：656-673.
[7]	Rumende CM.Risk Factors for multidrug-resistant tuberculosis[J].Acta Med Indones，2018，50（1）：1-2.
[8]	Workicho A，Kassahun W，Alemseged F.Risk factors for multidrug-resistant tuberculosis among tuberculosis patients：a case-control study[J].Infect Drug Resist，2017，10（2）：91-96.
[9]	徐飚.强化耐多药患者诊治管理控制耐多药结核病流行[J].中国防痨杂志，2016，38（4）：245-247.
[10]	张玲.耐多药肺结核治疗及其影响因素分析[J].临床肺科杂志，2016，21（8）：1508-1511.
[11]	Ding P，Li X，Jia Z，et al.Multidrug-resistant tuberculosis（MDR-TB） disease burden in China：a systematic review and spatiotemporal analysis[J].BMC Infect Dis，2017，17（1）：57.
[12]	Amorim-Franco TM，Favrot L，Vergnolle O，et al.Mechanismbased inhibition of the mycobacterium tuberculosis branchedchain aminotransferase by D-and L-cycloserine[J].ACS Chem Bio，2017，12（5）：1235-1244.
[13]	余丽然，杨焕群，刘树周.环丝氨酸对结核分枝杆菌的耐药性及耐药机制探讨[J].海峡药学，2017，6（3）：132-133.
[14]	刘智，杨梁梓，傅佳鹏，等.利奈唑胺治疗耐多药肺结核临床疗效观察[J].临床肺科杂志，2017，22（7）：1173-1176.
[15]	Penuelas M，Candel FJ，Lejarraga C，et al.Activity of linezolid and tedizolid against clinical isolates of methicillinresistant and methicillin and linezolid resistant Staphylococcus aureus：anin vitrocomparison[J].Rev Esp Quimioter，2016，29（5）：255-258.